Table 2.

Antitumor activity grouped by CD8 status (N=48)

Antitumor activity	All	10-20% (n=35)	> 20% (n=13)
Objective response	39 (81.3, 70.2-92.3)	26 (74.3, 56.7-87.5)	13 (100, 75.3-100)
Best overall response
Complete response	5 (10.4)	5 (14.3)	0 (0)
Partial response	34 (70.8)	21 (60.0)	13 (100)
Stable disease	5 (10.4)	5 (14.3)	0 (0)
Progressive disease	2 (4.2)	2 (5.7)	0 (0)
Unknown	2 (4.2)*	2 (5.7)	0 (0)

Data are presented as No. (%, 95% CI) or No. (%)

Responses were assessed in accordance with RECIST version 1.1. Only confirmed responses were included

*Two patients exempted post-baseline efficacy assessments